ClinicalTrials.gg
CompletedNCT00570661SOJIAUpdated May 4, 2021Results posted

Open Label, Multicentre Trial to Assess Safety and Efficacy of ITF2357 in Active Systemic Juvenile Idiopathic Arthritis

A Phase 2 interventional study of ITF2357 in Active Systemic and Onset Juvenile Idiopathic Arthritis, sponsored by Italfarmaco. Completed at 5 sites in 2 countries. Open to participants aged 2 Years to 25 Years. Per ClinicalTrials.gov, last updated 2021-05-04.

Sponsored by Italfarmaco · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Sep 2006, registered Dec 2007).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
2 Years to 25 Years
Sex
All
01

Study summary

This study has the following objectives:

Primary objective:

  • To determine the safety and tolerability of oral ITF2357 in patients with active SOJIA with inadequate response or intolerance to standard therapy with oral steroids and methotrexate, with or without previously used biologic agents.

Secondary objectives:

  • to evaluate the effect of ITF2357 on disease activity in patients with active SOJIA
  • to investigate the possibility of steroid dose tapering in patients with active SOJIA during ITF2357 treatment
  • to assess the effect of ITF2357 on levels of circulating cytokines
  • to assess the pharmacokinetic properties of ITF2357
Read the detailed description

The present study has been designed in order to evaluate safety and tolerability of ITF2357 in patients with active SOJIA with inadequate response or intolerance to standard therapy with oral steroids and methotrexate, with or without previously used biologic agents, and to have a preliminary evaluation of efficacy of ITF2357 in the treatment of SOJIA.

ITF2357 will be administered orally at the daily cumulative dose of 1.5 mg/kg: this dose in children/young adults is considered roughly equivalent to the dose of 1 mg/kg/day in adults, which so far has been proven to be free of any relevant safety concerns both in healthy volunteers and in patients.

02

Conditions studied

  • Active Systemic
  • Onset Juvenile Idiopathic Arthritis

Browse trials for

03

In context

Arthritis, Juvenile

366 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.

This study's enrollment of 17 is below the median of 52 across 230 interventional studies indexed under Arthritis, Juvenile.

Browse Arthritis, Juvenile studies →

Lead sponsor

Italfarmaco is the lead sponsor of 35 studies on the registry; 5 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Established diagnosis of Systemic SOJIA according to ILAR criteria for at least six months before the study entry, with inadequate response or intolerance to standard therapy with oral and/or methotrexate, with or without previously used biologic agents.
  2. Active disease for at least one month prior to enrolment as defined by the following criteria:

    • Presence of arthritis plus at least one of the following:

      • Fever, defined as a body temperature >= 37,5 C degree at least once a day during at least five consecutive days or presence of typical SOJIA intermittent temperature chart
      • Rash, defined by presence of typical SOJIA salmon pink rash on the trunk and elsewhere during the febrile episodes
      • Serositis (pericarditis, pleuritis, peritonitis) confirmed by ultrasound and/or X-ray exploration or by presence of typical findings in the case of pericarditis
      • Lymphadenopathy, defined by lymph nodes enlargement to 1,5 cm or more localized anywhere within the body, and/or hepatomegaly and/or splenomegaly, confirmed by ultrasound evaluation and established after comparison to age standards for organ size
      • ESR >= 20 mm/h (first hour) and/or CRP >= 10 mg/L. in the absence of arthritis, two definite or one definite and one probable diagnostic criteria plus ESR >=20 mm/h (first hour) and/or CRP >=10 mg/L
  3. Age at enrolment between 2 and 25 years
  4. Age at first SOJIA diagnosis \< 16 years
  5. Previously introduced standard treatment of disease with steroids without satisfactory effect and concomitant treatment with oral steroids at a dose equivalent to >= 0,2 mg/kg/day of prednisolone, unmodified for at least four weeks before patient's enrolment
  6. In case of concomitant methotrexate treatment, it has to be on stable dose >= 10mg/m2 weekly for al least 4 weeks before pt enrollment
  7. Previous treatment with biologics, if any, during at least three months without satisfactory effect or with drug intolerability, discontinued for at least the period specified below before patient's enrolment:

    • Two months for etanercept
    • Six months for infliximab
  8. Other disease-modifying anti-rheumatic drugs possibly previously introduced have to be discontinued for a period of at least five half lives
  9. Concomitant nonsteroidal anti-inflammatory drugs, if any, on a stable dose for at least four weeks before patient's enrolment
  10. Female of , using safe measures
  11. Signed written before starting any study procedure

Exclusion criteria

Exclusion Criteria:

  1. Ongoing clinical relevant viral infection (eg.: Herpes Zoster, Ebstein barr, CMV, Systemic fungal infections or history of recurrent serious bacterial infection)
  2. History of macrophage activation syndrome
  3. illness i.e. any condition (including laboratory abnormalities) that in the opinion of the Investigator places the patient to unacceptable risk for adverse outcome if he/she were to participate in the study
  4. Psychiatric illness/social situations that would limit compliance with study medication and protocol requirements
  5. Congenital heart and/or central nervous system disorders
  6. Inherited metabolic diseases
  7. Positive serological testing for anti , anti and (to be performed at screening)
  8. Pregnant or lactating women
  9. Presence of
  10. Any previous evidence, irrespective of its severity, of coronary disease, cardiac rhythm abnormalities or congestive heart failure
  11. > 450 msec at screening evaluation
  12. Serum magnesium and potassium below the LLN at screening
  13. Unavoidable concomitant treatment with any drug known for potential risk of causing Torsades de Pointes
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    ITF2357

    ITF2357 hard gelatine capsules were administered orally, in fed conditions, at the cumulative daily dose of 1.5 mg/kg achieved by administration of 0.75 mg/kg at 12-hour interval for 4 weeks initially. The doses of 1.5 mg/kg/day were achieved by administration of an appropriate number of capsules of definite strength (dose strengths of 7.5, 10, 12.5, 15, 20 mg and 50 mg). Treatment was further prolonged up to 12 weeks in total if so suggested by the observed benefits and the lack of treatment-limiting toxicity

    Drug: ITF2357

Interventions

  • ITF2357 orally administered at the cumulative daily dose of 1.5 mg/kg, achieved by administration of different dose strengths identifiable by different colours.

    Also known as: Givinostat, histone deacetylase inhibitor

06

What researchers measure

Primary outcomes

  1. Number of Patients Completing Week 12 of Treatment

    The primary endpoint describes the number of patients who has completed week 12 of treatment with ITF2357, both in the Per protocol (PP) population and in the Intention to treat (ITT) population. ITF2357 hard gelatine capsules were administered orally, in fed conditions, at the cumulative daily dose of 1.5 mg/kg achieved by administration of 0.75 mg/kg at 12-hour interval for 4 weeks initially. The doses of 1.5 mg/kg/day were achieved by administration of an appropriate number of capsules of definite strength. Treatment was further prolonged up to 12 weeks in total if so suggested by the observed benefits and the lack of treatment-limiting toxicity.

    Time frame: At week 12

Secondary outcomes

  1. JIA Outcome Core Set Variables - Patient Global Assessment

    Patient/parent global Visual Analogue Scale (VAS) is from 0 to 100. The lower the score, the better the outcome.

    Time frame: At pretreatment visit, at weeks 2, 4, 6, 8, 10 and 12 (End of treatment), 1 month and 3 months follow up (FU1, FU3) in the PP and ITT populations respectively.

  2. JIA Outcome Core Set Variables - Physician Global Assessment

    Physician global Visual Analogue Scale (VAS) is from 0 to 100. The lower the score, the better the outcome.

    Time frame: At pretreatment visit, at weeks 2, 4, 6, 8, 10 and 12 (End of treatment), 1 month and 3 months follow up (FU1, FU3) in the PP and ITT populations respectively.

  3. JIA Outcome Core Set Variables - Number of Joints With Active Arthritis

    Number of active joints is from 0 to 75. The lower the score, the better the outcome.

    Time frame: At pretreatment visit, at weeks 2, 4, 6, 8, 10 and 12 (End of treatment), 1 month and 3 months follow up (FU1, FU3) in the PP and ITT populations respectively.

  4. JIA Outcome Core Set Variables - Number of Joints With Limitation

    Number of joints with limited range of motion is from 0 to 75. The lower the score, the better the outcome.

    Time frame: At pretreatment visit, at weeks 2, 4, 6, 8, 10 and 12 (End of treatment), 1 month and 3 months follow up (FU1, FU3) in the PP and ITT populations respectively.

  5. JIA Outcome Core Set Variables - CHAQ

    The Childhood Health Assessment Questionnaire (CHAQ) is from 0 to 3. For each of 8 section (Dressing and care, Getting up, Eating, Walking, Hygiene, Grasping, Catching, Activities) answers patient is getting 0,1,2 or 3 points (no difficulties, some difficulties, much difficulties, unable to do, respectively). The sum of points is then divided by 8 to get score 0 - 3. The lower the score, the better the outcome.

    Time frame: At pretreatment visit, at weeks 2, 4, 6, 8, 10 and 12 (End of treatment), 1 month and 3 months follow up (FU1, FU3) in the PP and ITT populations respectively.

  6. JIA Outcome Core Set Variables - ESR

    Measurements of erythrocyte sedimentation rate (ESR) were performed at the local laboratory cooperating with each study site.

    Time frame: At pretreatment visit, at weeks 2, 4, 6, 8, 10 and 12 (End of treatment), 1 month and 3 months follow up (FU1, FU3) in the PP and ITT populations respectively.

  7. Overall SFS Results - Sum of First Five Variables and Sum of Last Five Variables

    Modified Systemic Feature Score (SFS) variables included: * temperature, rash, lymph nodes, liver and spleen size, and clinical evidence of serositis (clinical variables) * ESR, CRP, leukocyte count, haemoglobin, thrombocyte count (laboratory variables). Items in both sets of variables were scored as present (1) or not present (0) based on predefined criteria. SFS data were presented as the sum of the first 5 items and the sum of the last 5 items. Each sum could range from a minimum of 0 to a maximum of 5.

    Time frame: At pretreatment visit, at weeks 2, 4, 6, 8, 10 and 12 (End of treatment), 1 month follow-up (FU1) in the PP and ITT populations respectively.

  8. Number of Patients With Presence or Absence of Each Item for Modified Systemic Feature Score (SFS) - Temperature

    SFS variables included: 1. temperature 2. rash 3. lymph nodes 4. liver and spleen size 5. clinical evidence of serositis (pericarditis, pleuritis or peritonitis) 6. ESR 7. CRP 8. leukocyte count 9. haemoglobin 10. thrombocyte count Temperature was scored as present or not present according to the following criterion: body temperature ≥ 37.5 °C at least once a day during at least five consecutive days or presence of typical SOJIA intermittent temperature chart (patients' temperature chart analysis).

    Time frame: Pre-treatment, Weeks 4, 8, 12, and 1-month follow up

  9. Number of Patients With Presence or Absence of Each Item for Modified Systemic Feature Score (SFS) - Typical SOJIA Rash

    SFS variables included: 1. temperature 2. rash 3. lymph nodes 4. liver and spleen size 5. clinical evidence of serositis (pericarditis, pleuritis or peritonitis) 6. ESR 7. CRP 8. leukocyte count 9. haemoglobin 10. thrombocyte count Typical SOJIA is a salmon pink rash on the trunk during the febrile episodes.

    Time frame: Pre-treatment, Weeks 4, 8, 12, and 1-month follow up

  10. Number of Patients With Presence or Absence of Each Item for Modified Systemic Feature Score (SFS) - Lymphadenopathy

    SFS variables included: 1. temperature 2. rash 3. lymph nodes 4. liver and spleen size 5. clinical evidence of serositis (pericarditis, pleuritis or peritonitis) 6. ESR 7. CRP 8. leukocyte count 9. haemoglobin 10. thrombocyte count Lymphadenopathy was scored as present or not present according to the following criterion: lymph node (nodes) enlargement to 1.5 cm or more, localized anywhere within the body.

    Time frame: Pre-treatment, Weeks 4, 8, 12, and 1-month follow up

  11. Number of Patients With Presence or Absence of Each Item for Modified Systemic Feature Score (SFS) - Hepatomegaly and/or Splenomegaly

    SFS variables included: 1. temperature 2. rash 3. lymph nodes 4. liver and spleen size 5. clinical evidence of serositis (pericarditis, pleuritis or peritonitis) 6. ESR 7. CRP 8. leukocyte count 9. haemoglobin 10. thrombocyte count Hepatomegaly and/or splenomegaly was scored as present if confirmed by ultrasound evaluation and established after comparison to age standards for organ size.

    Time frame: Pre-treatment, Weeks 4, 8, 12, and 1-month follow up

  12. Number of Patients With Presence or Absence of Each Item for Modified Systemic Feature Score (SFS) - Serositis

    SFS variables included: 1. temperature 2. rash 3. lymph nodes 4. liver and spleen size 5. clinical evidence of serositis (pericarditis, pleuritis or peritonitis) 6. ESR 7. CRP 8. leukocyte count 9. haemoglobin 10. thrombocyte count Serositis (pericarditis, pleuritis or peritonitis) was scored as present if confirmed by ultrasound and/or X-ray exploration or by the presence of typical ECG findings in the case of pericarditis.

    Time frame: Pre-treatment, Weeks 4, 8, 12, and 1-month follow up

  13. Number of Patients With Presence or Absence of Each Item for Modified Systemic Feature Score (SFS) - Erythrocyte Sedimentation Rate (ESR)

    SFS variables included: 1. temperature 2. rash 3. lymph nodes 4. liver and spleen size 5. clinical evidence of serositis (pericarditis, pleuritis or peritonitis) 6. ESR 7. CRP 8. leukocyte count 9. haemoglobin 10. thrombocyte count At the pre-treatment visit ESR was scored as present or not present according to the following criterion: ESR considered as elevated if ≥ 20 mm/h (first hour) At the subsequent visits ESR was scored 0 (Not present) if decreased by at least 30% as compared to pre-treatment value or normalized (\< 20 mm/h); score 1 (Present) if increased or decreased less than 30%.

    Time frame: Pre-treatment, Weeks 4, 8, 12, and 1-month follow up

  14. Number of Patients With Presence or Absence of Each Item for Modified Systemic Feature Score (SFS) - C-reactive Protein (CRP)

    SFS variables included: 1. temperature 2. rash 3. lymph nodes 4. liver and spleen size 5. clinical evidence of serositis (pericarditis, pleuritis or peritonitis) 6. ESR 7. CRP 8. leukocyte count 9. haemoglobin 10. thrombocyte count At the pre-treatment visit CRP was scored as present or not present according to the following criterion: CRP considered as elevated if ≥ 10 mg/L. At the subsequent visits CRP was scored 0 (Not present) if decreased by at least 30% compared to pre-treatment value or normalized (\< 10 mg/L); score 1 (Present) if increased or decreased less than 30%.

    Time frame: Pre-treatment, Weeks 4, 8, 12, and 1-month follow up

  15. Number of Patients With Presence or Absence of Each Item for Modified Systemic Feature Score (SFS) - White Blood Cell (WBC)

    SFS variables included: 1. temperature 2. rash 3. lymph nodes 4. liver and spleen size 5. clinical evidence of serositis (pericarditis, pleuritis or peritonitis) 6. ESR 7. CRP 8. leukocyte count 9. haemoglobin 10. thrombocyte count At the pre-treatment visit WBC was scored as present or not present according to the following criterion: Leukocyte count considered as elevated if ≥ 12 x 103/μL. At the subsequent visits WBC was scored 0 (Not present) if decreased by 20% compared to pre-treatment value or normalized (\< 12x103/μL); score 1 (Present) if increased or decreased less than 20%.

    Time frame: Pre-treatment, Weeks 4, 8, 12, and 1-month follow up

  16. Number of Patients With Presence or Absence of Each Item for Modified Systemic Feature Score (SFS) - Haemoglobin (Hb)

    SFS variables included: 1. temperature 2. rash 3. lymph nodes 4. liver and spleen size 5. clinical evidence of serositis (pericarditis, pleuritis or peritonitis) 6. ESR 7. CRP 8. leukocyte count 9. haemoglobin 10. thrombocyte count At the pre-treatment visit Hb was scored as present or not present according to the following criterion: Haemoglobin considered as lowered if below 11g/dL. At the subsequent visits Hb was scored 0 (Not present) if increased by 20% compared to pre-treatment value or normalized (\> 11 g/dL); score 1 (Present) if decreased or increased less than 20%.

    Time frame: Pre-treatment, Weeks 4, 8, 12, and 1-month follow up

  17. Number of Patients With Presence or Absence of Each Item for Modified Systemic Feature Score (SFS) - Thrombocytes

    SFS variables included: 1. temperature 2. rash 3. lymph nodes 4. liver and spleen size 5. clinical evidence of serositis (pericarditis, pleuritis or peritonitis) 6. ESR 7. CRP 8. leukocyte count 9. haemoglobin 10. thrombocyte count At the pre-treatment visit thrombocyte count was scored as present or not present according to the following criterion: Thrombocyte count considered as increased if ≥ 400x103/μL. At the subsequent visits thrombocyte count was scored 0 (Not present) if decreased by 20% compared to pretreatment value or normalized (\< 400x103/μL); score 1 (Present) if increased or decreased less than 20%.

    Time frame: Pre-treatment, Weeks 4, 8, 12, and 1-month follow up

  18. Number of Patients With JIA Plus SFS Clinical Improvement

    Clinical improvement at week 2, 4, 6, 8, 10 and 12 was evaluated on the basis of JIA30, JIA50 and JIA70 plus SFS (two points decrease in SFS) as per protocol. Patients were considered as improved and with positive therapeutic response if 3 or more JIA Core Set Variables improved by 30% and no more than one worsened by 30%. JIA50 and JIA70 were defined as an improvement of 3 or more JIA Core Set Variables by 50% and 70%, respectively, and no more than 1 worsened by 30%. Additionally two points decrease in Systemic Feature Score were considered as disease improvement.

    Time frame: At weeks 2, 4, 6, 8, 10 and 12.

  19. Number of Patients With Sufficient Therapeutic Response at Week 4 to Continue Treatment

    Therapeutic response at week 4 was considered sufficient by the Investigator if a decrease in Systemic Feature Score of 2 (at least one of the first five variables) and/or JIA30 response (or above: 50 or 70) was obtained.

    Time frame: At week 4

07

Results

Posted May 4, 2021

Participant flow

Seventeen patients were screened and enrolled in the study

Participant flow — Overall Study
MilestoneITF2357
Started17
Completed10
Not completed7
Withdrew: Disease worsening5
Withdrew: Unmet criterion of sufficient therapeutic response1
Withdrew: Adverse event1

Outcome measures

PrimaryNumber of Patients Completing Week 12 of Treatment

The primary endpoint describes the number of patients who has completed week 12 of treatment with ITF2357, both in the Per protocol (PP) population and in the Intention to treat (ITT) population. ITF2357 hard gelatine capsules were administered orally, in fed conditions, at the cumulative daily dose of 1.5 mg/kg achieved by administration of 0.75 mg/kg at 12-hour interval for 4 weeks initially. The doses of 1.5 mg/kg/day were achieved by administration of an appropriate number of capsules of definite strength. Treatment was further prolonged up to 12 weeks in total if so suggested by the observed benefits and the lack of treatment-limiting toxicity.

Time frame:
At week 12
Reported as:
Count of participants · Participants
Number of Patients Completing Week 12 of Treatment
ParticipantsITF2357 - PP PopulationITF2357 - ITT Population
Completers910
Non completers07
SecondaryJIA Outcome Core Set Variables - Patient Global Assessment

Patient/parent global Visual Analogue Scale (VAS) is from 0 to 100. The lower the score, the better the outcome.

Time frame:
At pretreatment visit, at weeks 2, 4, 6, 8, 10 and 12 (End of treatment), 1 month and 3 months follow up (FU1, FU3) in the PP and ITT populations respectively.
Reported as:
Mean · units on a scale
JIA Outcome Core Set Variables - Patient Global Assessment
units on a scaleITF2357 - PP PopulationITF2357 - ITT Population
Pre-treatment48.00 ± 22.5047.71 ± 21.45
Week 243.33 ± 21.1542.47 ± 21.30
Week 421.22 ± 14.0028.88 ± 22.48
Week 619.11 ± 15.0022.36 ± 18.33
Week 817.22 ± 14.5918.00 ± 13.99
Week 1017.44 ± 13.2822.33 ± 19.58
Week 1219.11 ± 14.5724.21 ± 20.89
FU118.11 ± 15.5326.56 ± 18.02
FU315.38 ± 15.3222.71 ± 17.85
SecondaryJIA Outcome Core Set Variables - Physician Global Assessment

Physician global Visual Analogue Scale (VAS) is from 0 to 100. The lower the score, the better the outcome.

Time frame:
At pretreatment visit, at weeks 2, 4, 6, 8, 10 and 12 (End of treatment), 1 month and 3 months follow up (FU1, FU3) in the PP and ITT populations respectively.
Reported as:
Mean · units on a scale
JIA Outcome Core Set Variables - Physician Global Assessment
units on a scaleITF2357 - PP PopulationITF2357 - ITT Population
Pretreatment48.00 ± 22.5047.71 ± 21.45
Week 243.33 ± 21.1542.47 ± 21.30
Week 421.22 ± 14.0028.88 ± 22.48
Week 619.11 ± 15.0022.36 ± 18.33
Week 817.22 ± 14.5918.00 ± 13.99
Week 1017.44 ± 13.2822.33 ± 19.58
Week 1219.11 ± 14.5724.21 ± 20.89
FU118.11 ± 15.5326.56 ± 18.02
FU315.38 ± 15.3222.71 ± 17.85
SecondaryJIA Outcome Core Set Variables - Number of Joints With Active Arthritis

Number of active joints is from 0 to 75. The lower the score, the better the outcome.

Time frame:
At pretreatment visit, at weeks 2, 4, 6, 8, 10 and 12 (End of treatment), 1 month and 3 months follow up (FU1, FU3) in the PP and ITT populations respectively.
Reported as:
Mean · units on a scale
JIA Outcome Core Set Variables - Number of Joints With Active Arthritis
units on a scaleITF2357 - PP PopulationITF2357 - ITT Population
Pretreatment9.33 ± 8.709.82 ± 9.11
Week 27.11 ± 8.628.41 ± 9.49
Week 43.78 ± 5.476.38 ± 9.26
Week 63.44 ± 5.293.57 ± 4.33
Week 83.67 ± 4.853.42 ± 4.29
Week 102.89 ± 4.542.75 ± 4.03
Week 123.44 ± 4.594.86 ± 4.74
FU13.00 ± 4.503.88 ± 4.49
FU33.33 ± 4.585.00 ± 6.05
SecondaryJIA Outcome Core Set Variables - Number of Joints With Limitation

Number of joints with limited range of motion is from 0 to 75. The lower the score, the better the outcome.

Time frame:
At pretreatment visit, at weeks 2, 4, 6, 8, 10 and 12 (End of treatment), 1 month and 3 months follow up (FU1, FU3) in the PP and ITT populations respectively.
Reported as:
Mean · units on a scale
JIA Outcome Core Set Variables - Number of Joints With Limitation
units on a scaleITF2357 - PP PopulationITF2357 - ITT Population
Pretreatment10.00 ± 9.5311.59 ± 14.00
Week 28.56 ± 9.7610.41 ± 14.42
Week 46.44 ± 7.207.44 ± 11.56
Week 65.78 ± 7.177.86 ± 11.91
Week 85.78 ± 6.634.67 ± 6.08
Week 105.22 ± 6.324.42 ± 5.65
Week 124.78 ± 5.658.79 ± 12.27
FU15.00 ± 5.927.94 ± 12.22
FU35.22 ± 5.707.20 ± 8.79
SecondaryJIA Outcome Core Set Variables - CHAQ

The Childhood Health Assessment Questionnaire (CHAQ) is from 0 to 3. For each of 8 section (Dressing and care, Getting up, Eating, Walking, Hygiene, Grasping, Catching, Activities) answers patient is getting 0,1,2 or 3 points (no difficulties, some difficulties, much difficulties, unable to do, respectively). The sum of points is then divided by 8 to get score 0 - 3. The lower the score, the better the outcome.

Time frame:
At pretreatment visit, at weeks 2, 4, 6, 8, 10 and 12 (End of treatment), 1 month and 3 months follow up (FU1, FU3) in the PP and ITT populations respectively.
Reported as:
Mean · units on a scale
JIA Outcome Core Set Variables - CHAQ
units on a scaleITF2357 - PP PopulationITF2357 - ITT Population
Pretreatment1.55 ± 0.541.75 ± 0.74
Week 21.13 ± 0.571.39 ± 0.87
Week 40.93 ± 0.551.23 ± 0.88
Week 60.75 ± 0.561.02 ± 0.82
Week 80.58 ± 0.500.85 ± 0.82
Week 100.55 ± 0.500.85 ± 0.87
Week 120.58 ± 0.410.95 ± 0.82
FU10.56 ± 0.391.02 ± 0.93
FU30.58 ± 0.510.85 ± 0.78
SecondaryJIA Outcome Core Set Variables - ESR

Measurements of erythrocyte sedimentation rate (ESR) were performed at the local laboratory cooperating with each study site.

Time frame:
At pretreatment visit, at weeks 2, 4, 6, 8, 10 and 12 (End of treatment), 1 month and 3 months follow up (FU1, FU3) in the PP and ITT populations respectively.
Reported as:
Mean · mm/hr
JIA Outcome Core Set Variables - ESR
mm/hrITF2357 - PP PopulationITF2357 - ITT Population
Pretreatment65.22 ± 23.0562.71 ± 31.76
Week 253.44 ± 26.5459.12 ± 30.90
Week 452.67 ± 22.6659.50 ± 34.71
Week 657.67 ± 20.6653.90 ± 22.35
Week 849.33 ± 33.7849.92 ± 31.20
Week 1058.33 ± 23.4059.25 ± 23.35
Week 1256.44 ± 40.7654.14 ± 37.07
FU139.89 ± 28.3246.31 ± 28.30
FU344.57 ± 25.0041.00 ± 25.02
SecondaryOverall SFS Results - Sum of First Five Variables and Sum of Last Five Variables

Modified Systemic Feature Score (SFS) variables included: * temperature, rash, lymph nodes, liver and spleen size, and clinical evidence of serositis (clinical variables) * ESR, CRP, leukocyte count, haemoglobin, thrombocyte count (laboratory variables). Items in both sets of variables were scored as present (1) or not present (0) based on predefined criteria. SFS data were presented as the sum of the first 5 items and the sum of the last 5 items. Each sum could range from a minimum of 0 to a maximum of 5.

Time frame:
At pretreatment visit, at weeks 2, 4, 6, 8, 10 and 12 (End of treatment), 1 month follow-up (FU1) in the PP and ITT populations respectively.
Reported as:
Mean · score on a scale
Overall SFS Results - Sum of First Five Variables and Sum of Last Five Variables
score on a scaleITF2357 - PP PopulationITF2357 - ITT Population
Sum of first 5 (clinical) variables - pre-treatment1.33 ± 0.710.94 ± 0.75
Sum of first 5 (clinical) variables - Week 20.44 ± 0.730.35 ± 0.61
Sum of first 5 (clinical) variables - Week 40.11 ± 0.330.31 ± 0.48
Sum of first 5 (clinical) variables - Week 60.11 ± 0.330.14 ± 0.36
Sum of first 5 (clinical) variables - Week 80.11 ± 0.330.17 ± 0.39
Sum of first 5 (clinical) variables - Week 100.11 ± 0.330.33 ± 0.65
Sum of first 5 (clinical) variables - Week 120.22 ± 0.440.29 ± 0.47
Sum of first 5 (clinical) variables - FU10.22 ± 0.440.20 ± 0.41
Sum of last 5 (lab) variables - pretreatment4.33 ± 1.004.24 ± 1.15
Sum of last 5 (lab) variables - week 22.44 ± 1.422.65 ± 1.17
Sum of last 5 (lab) variables - week 42.11 ± 0.932.25 ± 1.18
Sum of last 5 (lab) variables - week 61.56 ± 1.331.93 ± 1.21
Sum of last 5 (lab) variables - week 82.00 ± 1.661.92 ± 1.44
Sum of last 5 (lab) variables - week 102.00 ± 1.582.08 ± 1.38
Sum of last 5 (lab) variables - week 121.89 ± 1.452.07 ± 1.27
Sum of last 5 (lab) variables - FU12.22 ± 1.922.56 ± 1.67
SecondaryNumber of Patients With Presence or Absence of Each Item for Modified Systemic Feature Score (SFS) - Temperature

SFS variables included: 1. temperature 2. rash 3. lymph nodes 4. liver and spleen size 5. clinical evidence of serositis (pericarditis, pleuritis or peritonitis) 6. ESR 7. CRP 8. leukocyte count 9. haemoglobin 10. thrombocyte count Temperature was scored as present or not present according to the following criterion: body temperature ≥ 37.5 °C at least once a day during at least five consecutive days or presence of typical SOJIA intermittent temperature chart (patients' temperature chart analysis).

Time frame:
Pre-treatment, Weeks 4, 8, 12, and 1-month follow up
Reported as:
Number · participants
Number of Patients With Presence or Absence of Each Item for Modified Systemic Feature Score (SFS) - Temperature
participantsITF2357 - PP PopulationITF2357 - ITT Population
Temp - Pretreatment - absence410
Temp - Pretreatment - presence57
Temp - Week 4 - absence812
Temp - Week 4 - presence14
Temp - Week 8 - absence810
Temp - Week 8 - presence12
Temp - Week 12 - absence711
Temp - Week 12 - presence23
Temp - FU1 - absence712
Temp - FU1 - presence23
SecondaryNumber of Patients With Presence or Absence of Each Item for Modified Systemic Feature Score (SFS) - Typical SOJIA Rash

SFS variables included: 1. temperature 2. rash 3. lymph nodes 4. liver and spleen size 5. clinical evidence of serositis (pericarditis, pleuritis or peritonitis) 6. ESR 7. CRP 8. leukocyte count 9. haemoglobin 10. thrombocyte count Typical SOJIA is a salmon pink rash on the trunk during the febrile episodes.

Time frame:
Pre-treatment, Weeks 4, 8, 12, and 1-month follow up
Reported as:
Number · participants
Number of Patients With Presence or Absence of Each Item for Modified Systemic Feature Score (SFS) - Typical SOJIA Rash
participantsITF2357 - PP PopulationITF2357 - ITT Population
Rash - Pretreatment - absence614
Rash - Pretreatment - presence33
Rash - Week 4 - absence916
Rash - Week 4 - presence00
Rash - Week 8 - absence912
Rash - Week 8 - presence00
Rash - Week 12 - absence914
Rash - Week 12 - presence00
Rash - FU1 - absence916
Rash - FU1 - presence00
SecondaryNumber of Patients With Presence or Absence of Each Item for Modified Systemic Feature Score (SFS) - Lymphadenopathy

SFS variables included: 1. temperature 2. rash 3. lymph nodes 4. liver and spleen size 5. clinical evidence of serositis (pericarditis, pleuritis or peritonitis) 6. ESR 7. CRP 8. leukocyte count 9. haemoglobin 10. thrombocyte count Lymphadenopathy was scored as present or not present according to the following criterion: lymph node (nodes) enlargement to 1.5 cm or more, localized anywhere within the body.

Time frame:
Pre-treatment, Weeks 4, 8, 12, and 1-month follow up
Reported as:
Number · participants
Number of Patients With Presence or Absence of Each Item for Modified Systemic Feature Score (SFS) - Lymphadenopathy
participantsITF2357 - PP PopulationITF2357 - ITT Population
Lymphadenopathy - Pretreatment - absence613
Lymphadenopathy - Pretreatment - presence34
Lymphadenopathy - Week 4 - absence916
Lymphadenopathy - Week 4 - presence00
Lymphadenopathy - Week 8 - absence912
Lymphadenopathy - Week 8 - presence00
Lymphadenopathy - Week 12 - absence914
Lymphadenopathy - Week 12 - presence00
Lymphadenopathy - FU1 - absence916
Lymphadenopathy - FU1 - presence00
SecondaryNumber of Patients With Presence or Absence of Each Item for Modified Systemic Feature Score (SFS) - Hepatomegaly and/or Splenomegaly

SFS variables included: 1. temperature 2. rash 3. lymph nodes 4. liver and spleen size 5. clinical evidence of serositis (pericarditis, pleuritis or peritonitis) 6. ESR 7. CRP 8. leukocyte count 9. haemoglobin 10. thrombocyte count Hepatomegaly and/or splenomegaly was scored as present if confirmed by ultrasound evaluation and established after comparison to age standards for organ size.

Time frame:
Pre-treatment, Weeks 4, 8, 12, and 1-month follow up
Reported as:
Number · participants
Number of Patients With Presence or Absence of Each Item for Modified Systemic Feature Score (SFS) - Hepatomegaly and/or Splenomegaly
participantsITF2357 - PP PopulationITF2357 - ITT Population
Hepatomegaly - Pretreatment - absence816
Hepatomegaly - Pretreatment - presence11
Hepatomegaly - Week 4 - absence916
Hepatomegaly - Week 4 - presence00
Hepatomegaly - Week 8 - absence912
Hepatomegaly - Week 8 - presence00
Hepatomegaly - Week 12 - absence914
Hepatomegaly - Week 12 - presence00
Hepatomegaly - FU1 - absence916
Hepatomegaly - FU1 - presence00
SecondaryNumber of Patients With Presence or Absence of Each Item for Modified Systemic Feature Score (SFS) - Serositis

SFS variables included: 1. temperature 2. rash 3. lymph nodes 4. liver and spleen size 5. clinical evidence of serositis (pericarditis, pleuritis or peritonitis) 6. ESR 7. CRP 8. leukocyte count 9. haemoglobin 10. thrombocyte count Serositis (pericarditis, pleuritis or peritonitis) was scored as present if confirmed by ultrasound and/or X-ray exploration or by the presence of typical ECG findings in the case of pericarditis.

Time frame:
Pre-treatment, Weeks 4, 8, 12, and 1-month follow up
Reported as:
Number · participants
Number of Patients With Presence or Absence of Each Item for Modified Systemic Feature Score (SFS) - Serositis
participantsITF2357 - PP PopulationITF2357 - ITT Population
Serositis - Pretreatment - absence916
Serositis - Pretreatment - presence01
Serositis - Week 4 - absence915
Serositis - Week 4 - presence01
Serositis - Week 8 - absence912
Serositis - Week 8 - presence00
Serositis - Week 12 - absence913
Serositis - Week 12 - presence01
Serositis - FU1 - absence916
Serositis - FU1 - presence00
SecondaryNumber of Patients With Presence or Absence of Each Item for Modified Systemic Feature Score (SFS) - Erythrocyte Sedimentation Rate (ESR)

SFS variables included: 1. temperature 2. rash 3. lymph nodes 4. liver and spleen size 5. clinical evidence of serositis (pericarditis, pleuritis or peritonitis) 6. ESR 7. CRP 8. leukocyte count 9. haemoglobin 10. thrombocyte count At the pre-treatment visit ESR was scored as present or not present according to the following criterion: ESR considered as elevated if ≥ 20 mm/h (first hour) At the subsequent visits ESR was scored 0 (Not present) if decreased by at least 30% as compared to pre-treatment value or normalized (\< 20 mm/h); score 1 (Present) if increased or decreased less than 30%.

Time frame:
Pre-treatment, Weeks 4, 8, 12, and 1-month follow up
Reported as:
Number · participants
Number of Patients With Presence or Absence of Each Item for Modified Systemic Feature Score (SFS) - Erythrocyte Sedimentation Rate (ESR)
participantsITF2357 - PP PopulationITF2357 - ITT Population
ESR - Pretreatment - absence01
ESR - Pretreatment - presence916
ESR - Week 4 - absence25
ESR - Week 4 - presence711
ESR - Week 8 - absence44
ESR - Week 8 - presence58
ESR - Week 12 - absence35
ESR - Week 12 - presence69
ESR - FU1 - absence46
ESR - FU1 - presence510
SecondaryNumber of Patients With Presence or Absence of Each Item for Modified Systemic Feature Score (SFS) - C-reactive Protein (CRP)

SFS variables included: 1. temperature 2. rash 3. lymph nodes 4. liver and spleen size 5. clinical evidence of serositis (pericarditis, pleuritis or peritonitis) 6. ESR 7. CRP 8. leukocyte count 9. haemoglobin 10. thrombocyte count At the pre-treatment visit CRP was scored as present or not present according to the following criterion: CRP considered as elevated if ≥ 10 mg/L. At the subsequent visits CRP was scored 0 (Not present) if decreased by at least 30% compared to pre-treatment value or normalized (\< 10 mg/L); score 1 (Present) if increased or decreased less than 30%.

Time frame:
Pre-treatment, Weeks 4, 8, 12, and 1-month follow up
Reported as:
Number · participants
Number of Patients With Presence or Absence of Each Item for Modified Systemic Feature Score (SFS) - C-reactive Protein (CRP)
participantsITF2357 - PP PopulationITF2357 - ITT Population
CRP - Pretreatment - absence00
CRP - Pretreatment - presence917
CRP - Week 4 - absence58
CRP - Week 4 - presence48
CRP - Week 8 - absence46
CRP - Week 8 - presence56
CRP - Week 12 - absence56
CRP - Week 12 - presence48
CRP - FU1 - absence610
CRP - FU1 - presence36
SecondaryNumber of Patients With Presence or Absence of Each Item for Modified Systemic Feature Score (SFS) - White Blood Cell (WBC)

SFS variables included: 1. temperature 2. rash 3. lymph nodes 4. liver and spleen size 5. clinical evidence of serositis (pericarditis, pleuritis or peritonitis) 6. ESR 7. CRP 8. leukocyte count 9. haemoglobin 10. thrombocyte count At the pre-treatment visit WBC was scored as present or not present according to the following criterion: Leukocyte count considered as elevated if ≥ 12 x 103/μL. At the subsequent visits WBC was scored 0 (Not present) if decreased by 20% compared to pre-treatment value or normalized (\< 12x103/μL); score 1 (Present) if increased or decreased less than 20%.

Time frame:
Pre-treatment, Weeks 4, 8, 12, and 1-month follow up
Reported as:
Number · participants
Number of Patients With Presence or Absence of Each Item for Modified Systemic Feature Score (SFS) - White Blood Cell (WBC)
participantsITF2357 - PP PopulationITF2357 - ITT Population
WBC - Pretreatment - absence24
WBC - Pretreatment - presence713
WBC - Week 4 - absence610
WBC - Week 4 - presence36
WBC - Week 8 - absence710
WBC - Week 8 - presence22
WBC - Week 12 - absence710
WBC - Week 12 - presence24
WBC - FU1 - absence56
WBC - FU1 - presence410
SecondaryNumber of Patients With Presence or Absence of Each Item for Modified Systemic Feature Score (SFS) - Haemoglobin (Hb)

SFS variables included: 1. temperature 2. rash 3. lymph nodes 4. liver and spleen size 5. clinical evidence of serositis (pericarditis, pleuritis or peritonitis) 6. ESR 7. CRP 8. leukocyte count 9. haemoglobin 10. thrombocyte count At the pre-treatment visit Hb was scored as present or not present according to the following criterion: Haemoglobin considered as lowered if below 11g/dL. At the subsequent visits Hb was scored 0 (Not present) if increased by 20% compared to pre-treatment value or normalized (\> 11 g/dL); score 1 (Present) if decreased or increased less than 20%.

Time frame:
Pre-treatment, Weeks 4, 8, 12, and 1-month follow up
Reported as:
Number · participants
Number of Patients With Presence or Absence of Each Item for Modified Systemic Feature Score (SFS) - Haemoglobin (Hb)
participantsITF2357 - PP PopulationITF2357 - ITT Population
Hb - Pretreatment - absence36
Hb - Pretreatment - presence611
Hb - Week 4 - absence46
Hb - Week 4 - presence510
Hb - Week 8 - absence46
Hb - Week 8 - presence56
Hb - Week 12 - absence46
WBC - Week 12 - presence58
Hb - FU1 - absence48
Hb - FU1 - presence58
SecondaryNumber of Patients With Presence or Absence of Each Item for Modified Systemic Feature Score (SFS) - Thrombocytes

SFS variables included: 1. temperature 2. rash 3. lymph nodes 4. liver and spleen size 5. clinical evidence of serositis (pericarditis, pleuritis or peritonitis) 6. ESR 7. CRP 8. leukocyte count 9. haemoglobin 10. thrombocyte count At the pre-treatment visit thrombocyte count was scored as present or not present according to the following criterion: Thrombocyte count considered as increased if ≥ 400x103/μL. At the subsequent visits thrombocyte count was scored 0 (Not present) if decreased by 20% compared to pretreatment value or normalized (\< 400x103/μL); score 1 (Present) if increased or decreased less than 20%.

Time frame:
Pre-treatment, Weeks 4, 8, 12, and 1-month follow up
Reported as:
Number · participants
Number of Patients With Presence or Absence of Each Item for Modified Systemic Feature Score (SFS) - Thrombocytes
participantsITF2357 - PP PopulationITF2357 - ITT Population
Thrombocytes - Pretreatment - absence12
Thrombocytes - Pretreatment - presence815
Thrombocytes - Week 4 - absence915
Thrombocytes - Week 4 - presence01
Thrombocytes - Week 8 - absence811
Thrombocytes - Week 8 - presence11
Thrombocytes - Week 12 - absence914
Thrombocytes - Week 12 - presence00
Thrombocytes - FU1 - absence69
Thrombocytes - FU1 - presence37
SecondaryNumber of Patients With JIA Plus SFS Clinical Improvement

Clinical improvement at week 2, 4, 6, 8, 10 and 12 was evaluated on the basis of JIA30, JIA50 and JIA70 plus SFS (two points decrease in SFS) as per protocol. Patients were considered as improved and with positive therapeutic response if 3 or more JIA Core Set Variables improved by 30% and no more than one worsened by 30%. JIA50 and JIA70 were defined as an improvement of 3 or more JIA Core Set Variables by 50% and 70%, respectively, and no more than 1 worsened by 30%. Additionally two points decrease in Systemic Feature Score were considered as disease improvement.

Time frame:
At weeks 2, 4, 6, 8, 10 and 12.
Reported as:
Number · participants
Number of Patients With JIA Plus SFS Clinical Improvement
participantsITF2357 - PP PopulationITF2357 - ITT Population
JIA30 plus SFS - W2 - Clinical improvement711
JIA30 plus SFS - W2 - Absence of clinical improvement26
JIA30 plus SFS - W4 - Clinical improvement812
JIA30 plus SFS - W4 - Absence of clinical improvement15
JIA30 plus SFS - W6 - Clinical improvement812
JIA30 plus SFS - W6 - Absence of clinical improvement15
JIA30 plus SFS - W8 - Clinical improvement811
JIA30 plus SFS - W8 - Absence of clinical improvement16
JIA30 plus SFS - W10 - Clinical improvement811
JIA30 plus SFS - W10 - Absence of clinical improvement16
JIA30 plus SFS - W12 - Clinical improvement810
JIA30 plus SFS - W12 - Absence of clinical improvement17
JIA50 plus SFS - W2 - Clinical improvement711
JIA50 plus SFS - W2 - Absence of clinical improvement26
JIA50 plus SFS - W4 - Clinical improvement810
JIA50 plus SFS - W4 - Absence of clinical improvement17
JIA50 plus SFS - W6 - Clinical improvement811
JIA50 plus SFS - W6 - Absence of clinical improvement16
JIA50 plus SFS - W8 - Clinical improvement810
JIA50 plus SFS - W8 - Absence of clinical improvement17
JIA50 plus SFS - W10 - Clinical improvement89
JIA50 plus SFS - W10 - Absence of clinical improvement18
JIA50 plus SFS - W12 - Clinical improvement89
JIA50 plus SFS - W12 - Absence of clinical improvement18
JIA70 plus SFS - W2 - Clinical improvement610
JIA70 plus SFS - W2 - Absence of clinical improvement37
JIA70 plus SFS - W4 - Clinical improvement810
JIA70 plus SFS - W4 - Absence of clinical improvement17
JIA70 plus SFS - W6 - Clinical improvement810
JIA70 plus SFS - W6 - Absence of clinical improvement17
JIA70 plus SFS - W8 - Clinical improvement89
JIA70 plus SFS - W8 - Absence of clinical improvement18
JIA70 plus SFS - W10 - Clinical improvement89
JIA70 plus SFS - W10 - Absence of clinical improvement18
JIA70 plus SFS - W12 - Clinical improvement89
JIA70 plus SFS - W12 - Absence of clinical improvement18
SecondaryNumber of Patients With Sufficient Therapeutic Response at Week 4 to Continue Treatment

Therapeutic response at week 4 was considered sufficient by the Investigator if a decrease in Systemic Feature Score of 2 (at least one of the first five variables) and/or JIA30 response (or above: 50 or 70) was obtained.

Time frame:
At week 4
Reported as:
Number · participants
Number of Patients With Sufficient Therapeutic Response at Week 4 to Continue Treatment
participantsITF2357 - PP PopulationITF2357 - ITT Population
Therapeutic response811
Absence of therapeutic response16

Adverse events

Collected over At weeks 1, 2, 4, 6, 8, 10, 12 (end of treatment) and FU1 and FU3. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IT2357 - Safety Population0/17 (0%)2/17 (11.8%)14/17 (82.4%)
Most frequent serious events
Most frequent serious events
EventIT2357 - Safety Population
VaricellaInfections and infestations1/17
CellulitisInfections and infestations1/17
Most frequent other events
Showing 10 of 24
Most frequent other events
EventIT2357 - Safety Population
Oropharyngeal painRespiratory, thoracic and mediastinal disorders3/17
ArthritisMusculoskeletal and connective tissue disorders3/17
RashSkin and subcutaneous tissue disorders2/17
InfluenzaInfections and infestations2/17
InjuryInjury, poisoning and procedural complications1/17
Electrocardiogram QT prolongedInvestigations1/17
AtelectasisRespiratory, thoracic and mediastinal disorders1/17
FatigueGeneral disorders1/17
PyrexiaGeneral disorders1/17
DepressionPsychiatric disorders1/17

Baseline characteristics

Safety population: all recruited patients who received at least one dose of the study medication.

Age, Categorical
Age, Categorical(Participants)ITF2357
<=18 years15
Between 18 and 65 years2
>=65 years0
Age, Continuous
Age, Continuous(years)ITF2357
Mean11.18 ± 5.39
Sex: Female, Male
Sex: Female, Male(Participants)ITF2357
Female6
Male11
Region of Enrollment
Region of Enrollment(participants)ITF2357
Romania5
Serbia12
08

Study locations

5 sites
  • Clinica Institute Fundeni.Pediatric Clinic 258 Sos. Fundeni,
    Bucharest, 022328, Romania
  • Clinical Emergency Children Hospital "M.S. Curie" Paediatric Clinic no. I 20 Ctin. Brancoveanu Bvd., 041451 Bucharest 4th district
    Bucharest, 041451, Romania
  • University Clinical Centre NisClinic of Paediatrics Department for Rheumatology Bul Dr Zoran Djindjica
    Niš, Nis 18000, Serbia
  • Mother and Child Health Institute "Dr. Vukan Cupic" Clinic of Paediatrics Radoja Dakica
    Belgrade, Novi Belgrade 6-811070, Serbia
  • Institute of Rheumatology Belgrade Resavska
    Belgrade, 6911000, Serbia
09

References and documents

Publications

  • Vojinovic J, Damjanov N, D'Urzo C, Furlan A, Susic G, Pasic S, Iagaru N, Stefan M, Dinarello CA. Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2011 May;63(5):1452-8. doi: 10.1002/art.30238. PubMed 21538322 ↗
  • Vojinovic J, Damjanov N. HDAC inhibition in rheumatoid arthritis and juvenile idiopathic arthritis. Mol Med. 2011 May-Jun;17(5-6):397-403. doi: 10.2119/molmed.2011.00030. Epub 2011 Feb 4. PubMed 21308151 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2006 to primary completion in Aug 2008, 23 months.

Results were first posted in May 2021, 12 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2007
First posted
Dec 11, 2007
StartActual
Sep 12, 2006
Primary completionActual
Aug 25, 2008
CompletionActual
Jun 10, 2013
Results first posted
May 4, 2021
Last update
May 4, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00570661
Lead sponsor
Italfarmaco
Responsible party
Sponsor
First posted
Dec 11, 2007
Start date
Sep 12, 2006
Primary completion
Aug 25, 2008
Completion
Jun 10, 2013
Results posted
May 4, 2021
Last update
May 4, 2021

Study contacts

Nemanja Damjanov, MD, PhD
principal investigator · Institute of Rheumatology Belgrade

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Givinostat

Start the discussion